The oncologist

Use of GLP-1 receptor drugs and survival in women with type 2 diabetes and breast cancer

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Diabetes and obesity are associated with worse prognosis in women with breast cancer.

  • The role of glucagon-like peptide-1 receptor agonists (GLP-1RA) in breast cancer survival is not well understood.
  • There is a need to explore how GLP-1RA may affect outcomes in women diagnosed with breast cancer.
  • Current evidence suggests that diabetes and obesity could negatively influence breast cancer prognosis.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jul '24
Glucagon-Like Peptide 1 Receptor Agonists and Risk of 13 Obesity-Related Cancers in People with Type 2 Diabetes
top 2% journal
cited by 233 papers
research support, n.i.h., extramural
Feb '26
Treatment with GLP-1 Receptor Agonists is Linked to Better Results in Arteriovenous Fistulas
top 5% journal
journal article
May '26
Survival and Cancer Return Rates Linked to GLP-1 Receptor Agonist Treatment in Breast Cancer
top 2% journal
journal article
Dec '25
GLP-1 receptor drugs and their effects on 5-year risk of major amputation, death, heart attack, and stroke in people with severe limb blood flow problems
top 20% journal
journal article
Jan '26
GLP-1 Drugs and Their Role in Preventing Repeat Heart Attacks and Strokes in People with Type 2 Diabetes: Evidence from Across the Country
top 5% journal
journal article
Sep '25
Glucagon-like peptide-1 receptor drugs linked to lower death, heart, and mental health risks in people with psoriasis
top 5% journal
cited by 7 papers
journal article
Jun '25
Link between diabetes drugs that target GLP-1 receptors and ovarian cancer survival in a large patient group
top 10% journal
cited by 2 papers
journal article
Jun '26
Breast Cancer Outcomes Compared Between Diabetes Drugs and Weight-Loss Surgery
journal article
Mar '26
Heart and blood vessel outcomes of GLP-1 drugs in women with type 2 diabetes and breast cancer
top 20% journal
journal article
Nov '25
Drugs activating glucagon-like peptide-1 receptors are linked to fewer abdominal aortic aneurysm problems
top 5% journal
cited by 4 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief